ACXP

Acurx Pharmaceuticals · USD

Market closed US (NYSE / Nasdaq) · 09:30–16:00 · Mon 17:09 · approx

Deep AI analysis (big model)

No deep analysis yet. Portfolio holdings are analysed automatically; for any other stock, click “Request deep AI analysis” above.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals (ACXP) is a pharmaceutical company focused on developing and commercializing innovative treatments for rare diseases. It operates within the Healthcare sector.

HealthcareBiotechnologyPharmaceuticals

Ticker	ACXP
Name	Acurx Pharmaceuticals
Currency	USD
Sector	Healthcare

Reputation

😎

How liked 50/100

From 0 recent analysed stories — 0 good · 0 bad · 0 neutral. Trend: stable.

Reputation builds as news about this company is analysed.

Price history & forecast

30-day forecast — Linear regression, Holt's exponential smoothing, and drift, plus a news-adjusted consensus (sentiment tilt +0.00). Estimates only, not advice.

Candlestick, volume & news sentiment

…

good bad neutral closed

Open/high/low/close candles with volume beneath; hover for OHLC, change and volume. Dots mark analysed news by sentiment; shaded bands are when the market was closed. Day and Week show intraday detail; Month+ show daily candles. Step through time with ‹ ›.

Forecast accuracy (backtested)

No scored forecasts yet. Every visit records the day's forecast; once those predicted dates pass, this table fills in with how each method actually did (1 snapshot(s) recorded so far, none matured yet).

Technical analysis

NEUTRAL

9.78

RSI (14)i

1.80

SMA 20i

2.09

SMA 50i

3.44

SMA 200i

0.00%

1di

-0.00%

1wi

-15.62%

1mi

3.11%

30d voli

16.42

52w highi

1.35

52w lowi

-90.13%

from highi

-0.15

MACDi

Downtrend (50d below 200d)Oversold (RSI 10)MACD bullish crossover

Computed from 258 locally-stored price bars.

AI signals

HOLD 70% · long_term 2026-06-08 10:11

The stock has been in a downtrend with significant losses over the past week, and there are no recent positive news to counterbalance this. The long-term outlook remains unclear without new developments.

qwen2.5:3b